FDA Withholds Vaccine Safety Research Amid Internal Policy Realignment
, , , ,

FDA Withholds Vaccine Safety Research Amid Internal Policy Realignment

The U.S. Food and Drug Administration (FDA) has halted the publication of several research studies focused on the safety profiles of Covid-19 and shingles vaccines. The decision, which involved pulling research from medical journals and preventing the presentation of findings at professional conferences, has sparked internal debate regarding the agency’s oversight of scientific data. Officials […]
Pfizer Outperforms Q1 Estimates as Non-Covid Portfolio Gains Momentum
, , ,

Pfizer Outperforms Q1 Estimates as Non-Covid Portfolio Gains Momentum

Pfizer has kicked off the fiscal year with a strong financial performance, reporting first-quarter revenue of $14.45 billion. This figure represents a 5% year-over-year increase, comfortably exceeding market expectations and allowing the pharmaceutical giant to reaffirm its financial guidance for 2026. The results underscore a successful transition for the company as it moves beyond the […]
The GLP-1 Gold Rush: Is Big Pharma Facing a Dangerous Concentration Risk?
, , , ,

The GLP-1 Gold Rush: Is Big Pharma Facing a Dangerous Concentration Risk?

The global pharmaceutical industry is experiencing a seismic shift as weight-loss and diabetes medications, particularly GLP-1 receptor agonists, dominate the financial landscape. For the first time in fifteen years, obesity treatments have surpassed oncology as the leading driver of late-stage pipeline value. While this trend has propelled research and development returns for the world’s top […]
AstraZeneca’s Camizestrant Faces Regulatory Hurdle Over Clinical Trial Design
, , ,

AstraZeneca’s Camizestrant Faces Regulatory Hurdle Over Clinical Trial Design

AstraZeneca encountered a significant regulatory challenge this week after a U.S. Food and Drug Administration (FDA) advisory panel voted against the current clinical trial design for camizestrant, an experimental oral breast cancer medication. The panel reached a 6-3 decision, expressing skepticism regarding the methodology of the Phase 3 SERENA-6 trial. Notably, the rejection was not […]
Eli Lilly Boosts Annual Outlook as Weight-Loss Drug Demand Hits Record Highs
, , , ,

Eli Lilly Boosts Annual Outlook as Weight-Loss Drug Demand Hits Record Highs

Eli Lilly has delivered a robust financial performance in its latest quarter, significantly exceeding market expectations as global demand for its flagship GLP-1 medications, Mounjaro and Zepbound, continues to accelerate. The pharmaceutical leader reported revenue of $19.80 billion, marking a substantial 56% increase compared to the same period last year. This momentum has led the […]
Merck Reports Strong Q1 Revenue Growth Amid Strategic Pipeline Expansion
, , ,

Merck Reports Strong Q1 Revenue Growth Amid Strategic Pipeline Expansion

Merck has initiated the fiscal year with a robust financial performance, announcing first-quarter revenues of $16.29 billion. This result marks a 5% increase compared to the same period last year, successfully outpacing market expectations. The growth was largely propelled by the company’s flagship oncology treatment, Keytruda, which experienced a 12% rise in sales to reach […]
Eli Lilly’s Foundayo Gains Traction as Oral Weight-Loss Market Expands
, , ,

Eli Lilly’s Foundayo Gains Traction as Oral Weight-Loss Market Expands

Eli Lilly has announced a strong initial performance for its newly released oral weight-loss medication, Foundayo, which has already been adopted by over 20,000 patients in the weeks following its market debut. According to company leadership, the drug is currently maintaining a steady growth trajectory, with approximately 1,000 new patients initiating treatment each day. This […]
Pharma Titans AstraZeneca and GSK Outperform Q1 Expectations Amid Regulatory Uncertainty
, , ,

Pharma Titans AstraZeneca and GSK Outperform Q1 Expectations Amid Regulatory Uncertainty

AstraZeneca and GSK have started 2026 on a strong financial footing, delivering first-quarter results that comfortably surpassed market expectations. AstraZeneca reported a core earnings per share (EPS) of $2.58, beating the anticipated $2.53, while GSK posted a core EPS of £0.47, exceeding the projected £0.43. Both pharmaceutical giants have reaffirmed their full-year financial guidance, reflecting […]
Novartis CEO Sounds Alarm on Global Drug Access as Pricing Policies Shift
, , ,

Novartis CEO Sounds Alarm on Global Drug Access as Pricing Policies Shift

Novartis CEO Vas Narasimhan has issued a critical warning regarding the future of global pharmaceutical access, pointing to the long-term consequences of evolving U.S. drug pricing policies. As the United States moves toward aligning domestic drug costs with international benchmarks, the pharmaceutical industry is facing a fundamental shift in its economic model. Narasimhan suggests that […]